Anti-RUNX2 Rabbit Monoclonal Antibody for WB, IP, ELISA - Q13950

Core Product Specifications and Parameters

Biological Background: RUNX2 Function and Localization

• Runt-related transcription factor 2 (RUNX2), also known as Acute myeloid leukemia 3 protein (AML3), Core-binding factor subunit alpha-1 (CBFA1), and Osteoblast-specific transcription factor 2 (OSF2), is a DNA-binding transcription factor.
• RUNX2 is a master regulator of osteoblastic differentiation and skeletal morphogenesis, essential for osteoblast maturation and both intramembranous and endochondral ossification. Related references: PMID:28505335, PMID:28703881, PMID:28738062
• It binds the core consensus sequence 5'-PYGPYGGT-3' in enhancers and promoters of genes critical for osteogenesis and hematopoiesis, including osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3, and GM-CSF.
• In osteoblasts, RUNX2 synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) and inhibits KAT6B-dependent transcriptional activation.
• Subcellularly, RUNX2 localizes to both the nucleus and cytoplasm.
• Its expression is highly specific to osteoblasts, reflecting its pivotal role in bone formation.
• RUNX2 undergoes multiple post-translational modifications, including phosphorylation, methylation, and ubiquitination, which regulate its activity and stability, and is associated with disease variants linked to skeletal dysplasia.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 336–439 within the C-terminal region of human RUNX2; epitope recognition may be influenced by post-translational modifications or conformational context in this domain.
• For Western blot, use whole‑cell lysates from osteoblast‑like cell lines (e.g., Saos‑2, MG‑63) or osteoclast‑differentiated cultures, and expect a predominant band near 57 kDa; validate with appropriate loading controls.
• In immunoprecipitation, titrate the antibody amount against a fixed quantity of lysate and optimize lysis buffer conditions (e.g., RIPA with protease/phosphatase inhibitors) to preserve protein interactions.
• For ELISA, consider using a recombinant RUNX2 fragment spanning the immunogen sequence as the standard; check cross‑reactivity with mouse samples if applied to rodent disease models.
• Cross‑reactivity with mouse enables comparative studies in murine osteoblast cultures or transgenic bone models, but always verify performance in the specific tissue or cell type of interest.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio empowers diagnostic manufacturers, laboratories, and research institutes with seamless access to a comprehensive portfolio of IVD raw materials and tailored technical support. For bone biology and skeletal disorder research, we supply validated monoclonal antibodies such as this anti-RUNX2 antibody, along with matched antibody pairs, recombinant proteins, and bulk ancillary reagents. Our integrated sourcing model accompanies your project from initial concept through clinical application, delivering reliable, high-quality materials when you need them.